Abstract 5314
Background
Spiritual distress is prevalent in advanced disease, but often neglected, resulting in unnecessary suffering. Religion and/or spirituality have increasingly been recognized as key elements in patients’ experience of advanced illness. This study aims to explore spiritual care needs, experiences, preferences and examine the association between religious coping and quality of life among patients with advanced cancer.
Methods
Structured interviews were conducted with 135 patients in advanced cancer patients and their primary informal caregivers. Patients completed measures of QOL (McGill QOL questionnaire), religious coping (Brief Measure of Religious Coping [RCOPE] and Multidimensional Measure of Religion/ Spirituality), self-efficacy (General Self-Efficacy Scale), and sociodemographic variables. Both positive and negative religious coping and multiple dimensions of QOL (physical, physical symptom, psychological, existential, and support) were studied.
Results
The median age of the population was 60.2 years and majority of the subjects were Hindus. The study revealed greater use of positive religious coping was associated with better overall QOL as well as higher scores on the existential and support QOL dimensions and was also related to more physical symptoms. However, greater use of negative religious coping was related to poorer overall QOL. Most patients believed it was important for health care professionals to consider patient spiritual concerns within the medical setting. Spiritual care was reportedly lacking, primarily due to staff members’ de-prioritisation and lack of time.
Conclusions
This study demonstrates that spiritual concerns are common among advanced cancer patients, and that they are associated with poorer psychological well-being. Spiritual care is an essential but neglected component of care, according to patients and their caregivers across a range of countries. The findings of the present study support the relationship between spirituality and health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vibhay Pareek.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2182 - Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx
Presenter: Keiichi Ota
Session: Poster Display session 1
Resources:
Abstract
5255 - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
Presenter: Liang Zhao
Session: Poster Display session 1
Resources:
Abstract
4910 - Expression of PD-L1 in Chinese Patients with Common Cancers
Presenter: Min Zheng
Session: Poster Display session 1
Resources:
Abstract
4227 - The clearance of EGF by tumor-associated macrophages is suppressed by chemotherapeutic agent cisplatin
Presenter: Irina Larionova
Session: Poster Display session 1
Resources:
Abstract
5222 - VHIO-300 and a thousand one nights, a tale of Precision Medicine
Presenter: Ginevra Caratù
Session: Poster Display session 1
Resources:
Abstract
5668 - Matched Whole-Genome Sequencing and Whole-Exome Sequencing with Circulating Tumor DNA (ctDNA) Analysis are complementary modalities in clinical practice
Presenter: Robin Imperial
Session: Poster Display session 1
Resources:
Abstract
5772 - Exploring the role of genes associated with familial cancer syndromes on the development of multiple primary tumors
Presenter: Atanaska Mitkova
Session: Poster Display session 1
Resources:
Abstract
4784 - Doxorubicin resistance: early and advanced tumors can use two different strategies based on initial and profound abnormalities in microRNA expression signature
Presenter: Volodymyr Halytskiy
Session: Poster Display session 1
Resources:
Abstract
3456 - From tumor transcriptomes to underlying cell type proportions to better predict prognosis and response to treatments
Presenter: Yuna Blum
Session: Poster Display session 1
Resources:
Abstract
4976 - Optimization of automated germline DNA extraction from non-tumoral formalin-fixed paraffin embedded (FFPE) tissues
Presenter: Omar Youssef
Session: Poster Display session 1
Resources:
Abstract